Endocrine Abstracts

Posttreatment assessment of the disease activity and definition of cure of acromegaly, by measuring GH secretion, remains problematic. Furthermore, with our efforts to achieve tight biochemical control of the disease it is foreseeable that a proportion of patients may be rendered GH deficient (GHD). The aim of our study was to evaluate residual GH secretion in cured patients with acromegaly. The study was approved by the Hospital Ethical Committee and after informed consent, b...

Inhibin B is a product of the gonads and it is a marker for ovarian follicular development. We studied leptin, inhibin B and LH levels in two groups of patients with AN, at low weight (n=20, BMI=14.3 plus/minus 0.3 kg/m2) and after they reached goal weight and restore menstrual cycles (n=13, BMI 19.3 plus/minus 1.0 kg/m2). Nineteen eumenorrheic females (BMI 19.8 plus/minus 0.4 kg/m2) served as controls. At low weight in patients with AN, basal leptin (1.1 plus/minus 0.2 ng/L),...

The variables which might affect the reproductive function in recovered patients with anorexia nervosa (AN) were investigated. We studied 12 patients with partially (n=6) and fully recovered AN (n= 6). They were matched for age (22.5 plus/minus 1.8 vs. 23.2 plus/minus 1.7 yrs; p>0.05), body weight (50.3 plus/minus 2.1 vs. 56.7 plus/minus 2.3kg; p>0.05) and BMI (19.7 plus/minus 0.2 vs. 20.3 plus/minus 0.6 kg/m2, p>0.05). Partially recovered AN were amenorrhoeic while f...

Introduction: Fine-needle biopsy with cytologic evaluation remains the diagnostic test of choice to distinguish benign from malignant thyroid nodules, but fails to classify thyroid nodules in 15% to 30% of cases (indeterminate thyroid nodules-ITN). ‘Rule out’ molecular testing improves the diagnostic accuracy, with high sensitivity and negative predictive value, ranging from 86 to 96%. However, these tests are not widely available, and notably increase costs. <p ...

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETs can be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resection is the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are p...

Aim: To establish the effect of a supplement containing 250 mg red yeast rice extract, 525 mg berberine and 50 mg coenzyme Q10 on insulin sensitivity in patients with hypercholesterolemia and prediabetes.Methods: For this open, uncontrolled study, patients of age 30–75 years, with hypercholesterolemia (LDL cholesterol >130 mg/dl and triglycerides <300 mg/dl), and prediabetes without overt cardiovascular disease, untreated in the previous 6 m...

Introduction: The interaction between corticosteroids and protease inhibitors (PIs) is a clearly described drug interaction.Case report: A 44-year-old woman diagnosed with HIV category B3 diagnosed in 1989; severe lipodystrophy. In addition , HCV genotype IA. Bronchial asthma since 2000. Treatment with fluticasone 1 inh/24 h, salbutamol on demand, darunavir 800 mg/day and ritonavir 100 mg/day. He had known lipodystrophy since 2001 and the abdominal perim...

Aims (objectives): Energy intake and expenditure are regulated by different signals. One of the molecules implicated is islet amyloid polypeptide (IAPP or amylin), one of the major secretory products of β-cells of the pancreatic islets of Langerhans. It is a peptide that inhibits insulin and glucagon secretion, and can also act through the brain decreasing food intake and inhibiting gastric emptying. In this study, we investigated the potential effects of the chronic cent...

Aim: To compare the effectiveness and tolerability of Exenatide twice daily treatment of obese and morbidly obese type 2 diabetic (T2D) patients.Material and methods: To analyze data of obese and severe obese T2D patients initiated on Exenatide in our Endocrine clinics who complete one year of treatment. We separate patients in two groups: group A (BMI<40 kg/m2) and group B (BMI≥40 kg/m2). We did not include any modificati...

Aim: To assess the effectiveness, safety and tolerability of Exenatide twice daily treatment of type 2 diabetes and obesity.Material and methods: Data analysis of obese type 2 diabetic patients initiated on Exenatide therapy in our Endocrine clinics who complete 1 year of treatment.Results: We included 42 patients, 30 women (71.4%) and 12 men (28.6%), mean (±S.D.) age 57±10 and 9±7 years diabetes evolu...